Levodopa-Responsive Parkinsonism with Prominent Freezing and Abnormal Dopamine Transporter Scan Associated with SANDO Syndrome

Movement Disorders Clinical Practice

Volumn 2, Issue 3, 2015, Pages 304-307

  Batla, Amit ^a   Erro, Roberto ^a,b   Ganos, Christos ^a,c   Stamelou, Maria ^a,d,e   Bhatia, Kailash P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY OF ATHENS   (Greece)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

mitochondrial POLG; Parkinsonism; SANDO

Indexed keywords

DNA DIRECTED DNA POLYMERASE GAMMA; DOPAMINE TRANSPORTER; LEVODOPA;

ADULT; ARTICLE; ATAXIA; BELL PALSY; CASE REPORT; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA POLYMORPHISM; DYSARTHRIA; ELECTROMYOGRAPHY; GENE MUTATION; HUMAN; MALE; MIDDLE AGED; OPHTHALMOPLEGIA; PARKINSONISM; PERONEUS NERVE PARALYSIS; POLYNEUROPATHY; PRIORITY JOURNAL; SENSORY ATAXIC NEUROPATHY WITH DYSARTHRIA AND OPHTHALMOPARESIS SYNDROME; SENSORY NEUROPATHY; WEAKNESS; WRINKLE;

EID: 84963588218     PISSN: None     EISSN: 23301619     Source Type: Journal    
DOI: 10.1002/mdc3.12164     Document Type: Article

References (12)

1. Hanisch F, Kornhuber M, Alston CL, Taylor RW, Deschauer M, Zierz S. SANDO syndrome in a cohort of 107 patients with CPEO and mitochondrial DNA deletions. J Neurol Neurosurg Psychiatry 2014 Aug 20. pii: jnnp-2013-306748. doi: 10.1136/jnnp-2013-306748. [Epub ahead of print].
2. Brighina L, Saracchi E, Ferri F, et al. Fahr's disease linked to a novel SLC20A2 gene mutation manifesting with dynamic aphasia. Neurodegener Dis 2014;14:133–138.
3. National Institute for Mental Health. CGI. Clinical global impressions. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; 1976:217–222.
4. Stamelou M, Quinn NP, Bhatia KP. “Atypical” atypical parkinsonism: new genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy-a diagnostic guide. Mov Disord 2013;28:1184–1199.
5. Miguel R, Gago MF, Martins J, Barros P, Vale J, Rosas MJ. POLG1-related levodopa-responsive parkinsonism. Clin Neurol Neurosurg 2014;126:47–54.
6. Bandettini di Poggio M, Nesti C, Bruno C, Meschini MC, Schenone A, Santorelli FM. Dopamine-agonist responsive Parkinsonism in a patient with the SANDO syndrome caused by POLG mutation. BMC Med Genet 2013;14:1471–2350.
7. Orsucci D, Caldarazzo Ienco E, Mancuso M, Siciliano G. POLG1-related and other “mitochondrial Parkinsonisms”: an overview. J Mol Neurosci 2011;44:17–24.
8. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989;1:1269.
9. Houlden H, Singleton AB. The genetics and neuropathology of Parkinson's disease. Acta Neuropathol 2012;124:325–338.
10. Hudson G, Schaefer AM, Taylor RW, et al. Mutation of the linker region of the polymerase gamma-1 (POLG1) gene associated with progressive external ophthalmoplegia and Parkinsonism. Arch Neurol 2007;64:553–557.
11. Synofzik M, Asmus F, Reimold M, Schols L, Berg D. Sustained dopaminergic response of parkinsonism and depression in POLG-associated parkinsonism. Mov Disord 2010;25:243–245.
12. Betts-Henderson J, Jaros E, Krishnan KJ, et al. Alpha-synuclein pathology and Parkinsonism associated with POLG1 mutations and multiple mitochondrial DNA deletions. Neuropathol Appl Neurobiol 2009;35:120–124.